The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly for adults with Type 2, the most common form of the disease.
The agency on Thursday, September 18, 2014, cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with Type 2 diabetes, which affects over 26 million Americans or about 90 percent of the cases in the United States.
The drug is part of a new class of medicines called GLP-1 agonists, which spur the pancreas to create extra insulin after meals.
The F.D.A. approved Trulicity based on six studies in 3,342 patients that showed improvements in blood sugar control.
The drug will bear a boxed warning highlighting that rats tested with Trulicity had cases of thyroid cancer, though it is unclear whether they were caused by the drug. Lilly will be required to conduct follow-up studies.
The drug is part of a new class of medicines called GLP-1 agonists, which spur the pancreas to create extra insulin after meals.
The F.D.A. approved Trulicity based on six studies in 3,342 patients that showed improvements in blood sugar control.
The drug will bear a boxed warning highlighting that rats tested with Trulicity had cases of thyroid cancer, though it is unclear whether they were caused by the drug. Lilly will be required to conduct follow-up studies.
No comments:
Post a Comment